Dec 01, 2021 / 02:40PM GMT
Josh Schimmer - Evercore ISI - Analyst
All right. Welcome, everyone. It's Josh Schimmer from the Evercore ISI biotech team. Pleased to be joined by the team of -- from COMPASS Pathways. Fresh off some very exciting data, first of its kind for treatment of refractory depressions, showing that COMP360 or psilocybin can have a very dramatic, rapid, and sustained benefit for patients. We have the team here to dive into that as well. The Company I think released a little bit more data from the trial this morning; so maybe we can cover that as well. I will turn it over to Steve Schultz, Head of IR to kick things off for us.
Steve Schultz - COMPASS Pathways plc - SVP, IR
Thank you, Josh, and welcome, everybody. And thank you for taking the time to join us today. I just will note that we will be making some forward-looking statements during the course of today's presentation and as such, I would suggest that you refer to our SEC filings for risks associated with investing in COMPASS Pathways. And at this point, I'd like to then hand it off to our Chairman and CEO, George
Compass Pathways PLC at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers